- HOME
- 홈페이지 이용안내
논문 기본정보
Vemurafenib-associated neutrophilic panniculitis in a patient with metastatic amelanotic melanoma presenting as cancer of unknown primary origin
논문 개요
| 기관명 | NDSL |
|---|---|
| 저널명 | 中華皮膚科醫學雜誌 = Dermatologica Sinica |
| ISSN | 1027-8117, |
| ISBN |
논문저자 및 소속기관 정보
| 저자(한글) | Weng, Y.C.,Chiu, C.S.,Lin, T.H.,Shen, J.L.,Yang, C.S.,Chen, J.B. |
|---|---|
| 저자(영문) | |
| 소속기관 | |
| 소속기관(영문) | |
| 출판인 | |
| 간행물 번호 | |
| 발행연도 | 2016-01-01 |
| 초록 | The treatment of metastatic melanoma is challenging. BRAF gene mutation is found in 40-60% of melanoma cases, the most common being the V600E mutation. Vemurafenib was approved by the Food and Drug Administration in 2011 as target therapy for the treatment with BRAF V600 mutation-positive metastatic melanoma. We report a case of metastatic amelanotic melanoma with unknown primary cancer as the initial presentation. The patient presented with neutrophilic septal panniculitis 1 week after vemurafenib treatment, which is a rare cutaneous toxicity of BRAF inhibitor. We also review the current literature on management of BRAF inhibitor-related adverse skin effects. |
| 원문URL | http://click.ndsl.kr/servlet/OpenAPIDetailView?keyValue=03553784&target=NART&cn=NART75679098 |
| 첨부파일 |
추가정보
| 과학기술표준분류 | |
|---|---|
| ICT 기술분류 | |
| DDC 분류 | |
| 주제어 (키워드) | BRAF inhibitor,drug reaction,erythema nodosum,melanoma,panniculitis,vemurafenib |